Advanced lung cancer

Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at...


The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


Results from the phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational Sotorasib ( AMG 510 ) in...


Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...


The FDA ( U.S. Food and Drug Administration ) has approved the PD-1 inhibitor Libtayo ( Cemiplimab-rwlc; Cemiplimab ) for...


The FDA ( Food and Drug Administration ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; fam-Trastuzumab Deruxtecan ) for adult patients...


Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...


The U.S. Food and Drug Administration ( FDA ) has approved Lumakras ( Sotorasib ) as the first treatment for...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer (...


Preclinical evidence has suggested that Niraparib ( Zejula ), a poly (ADP-ribose) polymerase inhibitor, may synergise with PD-1 inhibitors. Pembrolizumab...


Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary...


The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg every three weeks...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


Five-year survival results from the pivotal phase 3 KEYNOTE-024 trial were presented at ESMO Virtual Congress 2020. Sustained, long-term...


Osimertinib ( Tagrisso ) is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation–positive advanced non–small-cell...


The U.S. Food and Drug Administration ( FDA ) has approved Gavreto ( Pralsetinib ) for the treatment of adult...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status...


Sintilimab ( Tyvyt ), an anti–programmed death 1 antibody, plus Pemetrexed and Platinum had revealed promising efficacy for nonsquamous non-small-cell...


Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour...